AMRX vs. RCKT, ZLAB, AMPH, CPRX, DCPH, GERN, GLPG, VERA, KROS, and AGIO
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Rocket Pharmaceuticals (RCKT), Zai Lab (ZLAB), Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), Deciphera Pharmaceuticals (DCPH), Geron (GERN), Galapagos (GLPG), Vera Therapeutics (VERA), Keros Therapeutics (KROS), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
Amneal Pharmaceuticals presently has a consensus price target of $8.25, indicating a potential upside of 22.22%. Rocket Pharmaceuticals has a consensus price target of $52.13, indicating a potential upside of 157.92%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
Rocket Pharmaceuticals received 362 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 72.18% of users gave Rocket Pharmaceuticals an outperform vote.
In the previous week, Rocket Pharmaceuticals had 10 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Rocket Pharmaceuticals and 9 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat Rocket Pharmaceuticals' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.
Amneal Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.76%. Amneal Pharmaceuticals' return on equity of 234.06% beat Rocket Pharmaceuticals' return on equity.
Amneal Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 17.5% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Amneal Pharmaceuticals beats Rocket Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
